<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="55602"><DrugName>hib polysaccharide-tetanus toxoid conjugate vaccine (meningitis), LG Life Sciences</DrugName><DrugNamesKey><Name id="42972024">Euhib</Name></DrugNamesKey><DrugSynonyms><Name><Value>hib polysaccharide-tetanus toxoid conjugate vaccine (meningitis), LG Life Sciences</Value></Name><Name><Value>LBVH-0101</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Euhib</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="30057">LG Life Sciences Ltd</CompanyOriginator><CompaniesPrimary><Company id="30057">LG Life Sciences Ltd</Company><Company id="1073834">Tianjin Biochem Pharmaceutical Co Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="55602" type="Drug"><TargetEntity id="681465" type="siDrug">LBVH-0101</TargetEntity></SourceEntity><SourceEntity id="1073834" type="Company"><TargetEntity id="5001199249" type="organizationId">Tianjin Biochem Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="30057" type="Company"><TargetEntity id="4295882492" type="organizationId">LG Life Sciences Ltd</TargetEntity></SourceEntity><SourceEntity id="145" type="ciIndication"><TargetEntity id="1410" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1803" type="ciIndication"><TargetEntity id="G00" type="ICD10"></TargetEntity><TargetEntity id="320" type="ICD9"></TargetEntity><TargetEntity id="10027202" type="MEDDRA"></TargetEntity><TargetEntity id="D016920" type="MeSH"></TargetEntity><TargetEntity id="-373187665" type="omicsDisease"></TargetEntity><TargetEntity id="893" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Bacterial meningitis - South Korea - Jan-2012</FirstLaunched><FirstLaunched>Haemophilus influenzae infection - South Korea - Jan-2012</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="145">Haemophilus influenzae infection</Indication><Indication id="1803">Bacterial meningitis</Indication></IndicationsPrimary><ActionsSecondary><Action id="12379">Therapeutic vaccine</Action><Action id="12378">Prophylactic vaccine</Action><Action id="1594">Antibacterial</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra></EphmraCodes><LastModificationDate>2015-05-28T12:32:55.000Z</LastModificationDate><ChangeDateLast>2018-09-11T00:00:00.000Z</ChangeDateLast><AddedDate>2006-06-26T12:42:13.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="30057" linkType="Company"&gt;LG Life Sciences&lt;/ulink&gt; has developed and launched Euhib (presumed to be LBVH-0101),   an injectable vaccine that contains a haemophilus influenzae type B (hib) polysaccharide conjugated with tetanus toxoid, for the potential prevention   of meningitis [&lt;ulink linkID="675541" linkType="Reference"&gt;675541&lt;/ulink&gt;], [&lt;ulink linkID="973348" linkType="Reference"&gt;973348&lt;/ulink&gt;], [&lt;ulink linkID="1155605" linkType="Reference"&gt;1155605&lt;/ulink&gt;], [&lt;ulink linkID="1260007" linkType="Reference"&gt;1260007&lt;/ulink&gt;].  By January 2012, the vaccine had been launched. It is targeted at children under 24 months with meningitis [&lt;ulink linkID="1260007" linkType="Reference"&gt;1260007&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company, in collaboration with &lt;ulink linkID="1073834" linkType="Company"&gt;Tianjin Biochem Pharmaceutical&lt;/ulink&gt;, is investigating the vaccine in China. In July 2012, plans were being made to conduct trials there [&lt;ulink linkID="1327641" linkType="Reference"&gt;1327641&lt;/ulink&gt;], [&lt;ulink linkID="1329802" linkType="Reference"&gt;1329802&lt;/ulink&gt;]. In July 2013, a clinical trial application (CTA) was filed in China; in March 2015, the CTA was approved [&lt;ulink linkID="1663630" linkType="Reference"&gt;1663630&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;It was presumed that the company was developing the  vaccine as potential treatment of   meningitis. In December 2010, phase III development appeared to be ongoing [&lt;ulink linkID="1155605" linkType="Reference"&gt;1155605&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In December 2007, the vaccine was  listed in the company's pipeline as in phase III development [&lt;ulink linkID="969986" linkType="Reference"&gt;969986&lt;/ulink&gt;]. By August 2008, a multicenter, comparative, two parallel group, single-blind, phase III trial (&lt;ulink linkID="72669" linkType="Protocol"&gt;NCT01251133&lt;/ulink&gt;) of hib vaccine versus Hiberix in infants was initiated [&lt;ulink linkID="973348" linkType="Reference"&gt;973348&lt;/ulink&gt;]. In March 2010, the vaccine was still listed as being in phase III development [&lt;ulink linkID="1155605" linkType="Reference"&gt;1155605&lt;/ulink&gt;], [&lt;ulink linkID="1115303" linkType="Reference"&gt;1115303&lt;/ulink&gt;]. In January 2012, it was reported that in clinical trials, all healthy infants immunized with Euhib two, four and six months after birth produced antibodies against hib [&lt;ulink linkID="1260007" linkType="Reference"&gt;1260007&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, the vaccine was  listed in the company's pipeline as in phase II development [&lt;ulink linkID="970367" linkType="Reference"&gt;970367&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By May 2006, the vaccine was in preclinical development [&lt;ulink linkID="675541" linkType="Reference"&gt;675541&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-01-01T00:00:00.000Z</StatusDate><Source id="1260007" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-01-01T00:00:00.000Z</StatusDate><Source id="1260007" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-04T00:00:00.000Z</StatusDate><Source id="1327641" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1073834">Tianjin Biochem Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-04T00:00:00.000Z</StatusDate><Source id="1327641" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-12-31T00:00:00.000Z</StatusDate><Source id="969986" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-12-31T00:00:00.000Z</StatusDate><Source id="969986" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-05-25T00:00:00.000Z</StatusDate><Source id="675541" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-05-25T00:00:00.000Z</StatusDate><Source id="675541" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1663630" linkType="reference" linkID="1663630"&gt;1663630&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1073834">Tianjin Biochem Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22235">LG Chem Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="28971">Republic of Korea Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="137970" title="Korean MIHWAF to fund development of LG Life Sciences' Euhib"></Deal><Deal id="142049" title="Tianjin Biochem Pharmaceutical to develop and commercialize LG Life Sciences' Euhib in China"></Deal></Deals><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>